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Objective:Carotid endarterectomy (CEA) is the standard treatment of carotid stenosis for symptomatic and asymptomatic
patients. Carotid angioplasty and stenting (CAS), however, has been proposed as alternative therapy for patients deemed
at high-risk for CEA. This study examined 30-day adjudicated outcomes in a contemporary series of CEAs and assessed
the validity of criteria used to define a potential high-risk patient population for CEA.
Methods: Patients undergoing isolated CEA in private sector hospitals between Jan 1, 2005, and Dec 31, 2006, were
identified using the prospectively gatheredNational Surgical Quality Improvement Program database. The primary study
end points were 30-day stroke and death rates. Demographic, preoperative, and intraoperative variables were examined
using multivariate models to identify variables associated with the study end points. Variables used to define systemic
“high-risk” patients in the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) study (active cardiac disease, severe chronic obstructive pulmonary disease, and octogenarian status) were
examined individually and in composite fashion for association with study endpoints.
Results: Of the 3949 CEAs performed, 59% were in men, 30% were “high-risk” (19% age >80), and 43% had a previous
neurologic event. The 30-day stroke rate was 1.6%, the death rate was 0.7%, and combined stroke/death rate was 2.2%.
Multivariate analysis showed that intraoperative transfusion (odds ratio [OR], 5.95; 95% confidence interval [CI],
1.71-20.66; P .005), prior major stroke (OR, 5.34; 95% CI, 2.96-9.64; P< .0001), shorter height (surrogate for small
artery size; OR, 1.09; 95% CI, 1.02-1.16; P  .010), and increased anesthesia time (OR, 1.02; 95% CI, 1.00-1.03; P 
.008) were predictive of stroke. Critical limb ischemia (OR, 12.72; 95% CI, 3.49-46.40; P< .0001) and poor functional
status (OR, 7.05; 95% CI, 2.95-16.82; P < .0001) were independent correlates of death. Systemic high-risk variables,
either combined or individually, did not increase risk of stroke or death on multivariate analysis.
Conclusion: CEA is associated with favorable 30-day outcomes across a spectrum of patient comorbidity features
including octogenarian status. Anatomic and technical features are the important predictors of perioperative stroke,
whereas critical limb ischemia and poor functional status are important predictors of death for patients undergoing CEA.
These data refute the concept that CAS is preferred for patients deemed high-risk by virtue of systemic comorbidities.
(J Vasc Surg 2009;49:331-9.)Randomized controlled trials have shown that carotid
endarterectomy (CEA) significantly reduces the long-term
risk of subsequent stroke from carotid artery stenosis for
both symptomatic1-3 and asymptomatic4-6 patients. Recent
advances in endovascular therapies, however, have led some
to propose carotid angioplasty and stenting (CAS) as ap-
propriate alternative treatment for carotid artery stenosis.
In 2004 the United States Food and Drug Administra-
tion (FDA) approved the use of CAS for treatment of
carotid stenosis for so-called high-risk surgical patients.
The FDA’s decision was based primarily on the Stenting
and Angioplasty with Protection in Patients at High Risk
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doi:10.1016/j.jvs.2008.09.018for Endarterectomy (SAPPHIRE) trial,7,8 a multicenter,
randomized controlled trial designed to prove the nonin-
feriority of CAS vs CEA in high-risk surgical patients. The
SAPPHIRE trial has been criticized for a number of meth-
odologic and statistical problems.9-12 One such criticism is
the high 30-day stroke/death rate among patients under-
going CEA (5.4%) even though 70% of the patients
included in the study had asymptomatic disease. Previous
consensus documents indicate that for patients with asymp-
tomatic carotid stenosis to realize benefit after CEA, the
perioperative stroke/death rate should be 3%.13
Recent data from statewide and national registries as
well as large single-center series have shown that perioper-
ative complication rates after surgical treatment of carotid
stenosis14-21 are in fact, quite low. However, many of these
studies have been criticized for lack of 30-day adjudication
by an independent examiner. In addition, many such stud-
ies used discharge data from administrative databases and
therefore may have underestimated the true perioperative
complication rate after CEA.
In 2004 the American College of Surgeons (ACS)
started its own arm of the National Surgical Quality Im-
provement Program (NSQIP) and offered it to any inter-
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community medical centers were participating in the pro-
gram by 2006. This presented us with a unique opportunity
to examine 30-day adjudicated outcomes in a contempo-
rary series of CEAs using NSQIP methodology, which has
previously been validated.22,23 We also sought to assess the
validity of criteria used to define high-risk surgical patients
in studies such as the SAPPHIRE trial.
METHODS
Database. Approval to use the ACS NSQIP database
was obtained from both the ACS NSQIP and the Massa-
chusetts General Hospital Institutional Review Board. A
detailed description of the NSQIP study methods has been
previously published and validated.22 Since its inception in
1994, the program’s success within the Veterans Affairs
(VA) hospitals has led to its subsequent extension into and
validation within the private sector hospitals.23 By October
2004, the ACS had started its own arm of the NSQIP and
offered the program to all interested private hospitals,
including both academic and community centers. In 2005,
37 institutions participated in the program, and the num-
ber had increased to 121 by 2006.
For each participating hospital, patients undergoing
major surgical procedures are identified. A sample of pa-
tients is then selected using the 8-day cycle to prevent bias
in choosing cases.22 Preoperative risk factors, intraopera-
tive variables, and 30-day postoperative mortality and mor-
bidity outcomes are collected, validated, and submitted by
a trained and audited surgical clinical nurse–reviewer des-
ignated by the ACS. The database is maintained by third-
party organizations contracted by the ACS.
Patient selection. The ACSNSQIP database was que-
ried to identify patients undergoing CEA between 2005
and 2006 using the Current Procedural Terminology
(CPT) codes 35301 and 35390. Cases were selected in
which CEA was the primary procedure. Patients undergo-
ing other major concurrent procedures, including cardiac
surgeries and carotid artery angiograms, were excluded.
Indication for undergoing CEA (ie symptomatic vs asymp-
tomatic and percent stenosis) is not available in the data-
base. In particular, although history of previous neurologic
event is available, neither the laterality nor the timing of
such event can be obtained from the database and thus we
were not able to determine which patients were symptom-
atic at the time of CEA.
Definitions and end points. Definitions of preopera-
tive variables included in the NSQIP database are listed in
the Appendix. We identified a subgroup of systemic “high-
risk” patients using criteria similar to that defined by the
SAPPHIRE study.7 The “high-risk” group included those
aged 80 years, those with significant cardiac disease (ac-
tive congestive heart failure, myocardial infarction [MI]6
months before CEA, or angina 1 month before CEA),
and those with severe chronic obstructive pulmonary
disease. Various anatomic high-risk factors used in the
SAPPHIRE study (eg, contralateral carotid occlusion, con-
tralateral laryngeal-nerve palsy, previous radical neck sur-gery/radiation therapy to the neck) are not available in the
NSQIP database and therefore were not addressed in this
study.
The principal study end points were 30-day stroke and
death. Thirty-day stroke is defined as “patient develops an
embolic, thrombotic, or hemorrhagic vascular accident or
stroke with motor, sensory, or cognitive dysfunction (eg
hemiplegia, hemiparesis, aphasia, sensory deficit, impaired
memory) that persists for 24 or more hours.” The assess-
ment of these outcomes were made by the trained clinical
nurse–reviewer using a variety of methods, including med-
ical record reviews, and if necessary, letters or phone calls to
patients.
Statistical analysis. Statistical analysis was performed
using SPSS 15.0 software (SPSS Inc, Chicago, Ill). The
Fisher exact test and 2 analysis were used to compare
categoric variables, and the t test was used for continuous
variables. Univariate analysis was performed between the
30-day outcome vs preoperative and intraoperative vari-
ables. Variables included as “high-risk” were assessed com-
bined or individually in univariate analysis. The significant
variables (P  .05) were then considered in a multivariate
logistic regression model to identify independent predic-
tors of stroke or death. In cases where preoperative and
intraoperative variables might duplicate each other in as-
sessing risks, only the one with the highest significance was
entered into the multivariate model. Odds ratios were
reported with 95% confidence intervals. The additive effect
of “high-risk” variables was assessed using linear by linear
association test.
RESULTS
During the study period, 3949 isolated CEAs were
performed, consisting of 872 CEAs in 2005 and 3077
CEAs in 2006, with no significant difference in stroke/
death rate by year of treatment. Demographic and clinical
features as well as intraoperative variables of the study
group are compiled in Table I. The criteria for “high risk”
were met by 30% of the patients, with 19% being those aged
80 years. A previous neurologic event had occurred in
43%, and 6.7% were hemiplegic. The 30-day stroke rate was
1.6% (62 of 3949), the death rate was 0.7% (26 of 3049),
and the combined stroke/death rate was 2.2% (85 of
3949). Only three patients had a fatal stroke. The rates for
stroke, death, or combined stroke/death were not signifi-
cantly different between octogenarians and non-octoge-
narians, with stroke at 1.5% vs 1.6% (P .85), death at 0.9%
vs 0.6% (P  .28), and stroke/death at 2.3% vs 2.1% (P 
.75). Among patients without any previous neurologic
events, the 30-day stroke rate was 1.3%, the death rate was
0.5%, and the combined stroke/death rate was 1.7%. The
average total length of stay was 2.7 4.2 days, and 39 of 62
strokes (62.9%) and 12 of 26 deaths (46.2%) were observed
before discharge from the initial hospitalization.
Univariate analysis for stroke is summarized in Table II.
Although history of major neurologic event, defined as
hemiplegia and cerebral vascular accident (CVA) with re-
sidual deficit, was associated with an increased risk of post-
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as transient ischemic attack (TIA) and CVA with no resid-
ual deficit, was not. Variables included in “high-risk,”
either combined or individually, did not affect the rate of
stroke after CEA.
Candidate variables from the univariate analysis of
stroke were selected and used to construct a multivariate
model (Table III). History of CVA with neurologic deficit
was not included in the model because of overlap with
hemiplegia. Multivariate analysis showed need for intraop-
erative transfusion, previous history of hemiplegia, shorter
height (surrogate for small artery size), and increased anes-
thesia time to be predictive of stroke.
Univariate analysis for variables associated with periop-
erativemortality is reported in Table IV. A larger number of
systemic comorbidities were significantly associated with
death compared with stroke. The “high-risk” group, for
example, had higher rate of perioperative mortality after
CEA. However, when individual variables included in the
Table I. Democratic, clinical, and intraoperative features
Characteristic % (No)
Mean  SD
[range]
Age, y 70.4  9.5 (21-89)*
Male 59.0 (2330/3949)
“High-risk” 29.7 (1174/3949)
Age 80 y 18.7 (737/3949)
Significant cardiac disease 5.0 (198/3949)
Active congestive heart failure 1.3 (53/3949)
Recent myocardial infarction 1.5 (60/3949)
Recent angina 2.7 (107/3949)
Severe COPD 8.9 (351/3949)
Previous PTCA 17.5 (691/3949)
Previous cardiac surgery 24.7 (977/3949)
Hypertension 85.6 (3380/3949)
Chronic renal insufficiency** 16.2 (600/3708)
Dialysis dependent 0.9 (35/3949)
IDDM 8.8 (347/3949)
Peripheral vascular disease 10.0 (394/3949)
Critical limb ischemia 1.1 (42/3949)
Previous neurologic event 43.2 (1704/3949)
Hemiplegia 6.7 (263/3949)
Cerebrovascular accident
With deficit 15.1 (595/3949)
Without deficit 7.6 (302/3949)
Transient ischemic attack 38.5 (1127/3949)
Current smoker 37.3 (1078/3949)
Dependent functional status*** 6.3 (247/3949)
Previous CEA 0.9 (34/3949)
Total anesthesia time (min) 187.3  61.5 [44-1592]
Total length of stay (days) 2.7  4.2 [0-92]
CEA, Carotid endarterectomy; COPD, chronic obstructive pulmonary dis-
ease; IDDM, insulin dependent diabetes mellitus; PTCA, percutaneous
transluminal coronary angioplasty; PVD, peripheral vascular disease.
*Patients aged 90 years were coded as 90 and were excluded from
average age calculation.
**Defined as serum creatinine  1.5 mg/dL.
***Dependent function status is defined as needing assistance to perform
activities of daily living and does not include an individual who functions
independently but uses prosthesis, equipment, or devices.“high-risk” group were examined, only a history of majorcardiac disease was associated with higher rate of postoper-
ative death.
Candidate variables from the univariate analysis of peri-
operative mortality were selected and used to construct a
multivariate model (Table III). Again, in cases where
preoperative/intraoperative variables might duplicate each
other in assessing risks, only the one with the highest
significance was entered into the multivariate model. Be-
cause only 26 deaths occurred, only the first two variables
with the highest significance—critical limb ischemia (CLI)
and poor functional status—were considered to be reliable
independent predictors of death. Variables included as
“high-risk,” either combined or individually, did not in-
crease the risk of death on multivariate analysis.
The additive effect of “high-risk” variables was assessed
using linear by linear association test. No significant rela-
tionship was found between the number of “high-risk”
variables and the stroke rate. However, a significant linear
relationship existed between the number of “high-risk”
variables and mortality rate, where mortality was 14.3%
among those with all three of the “high-risk” variables;
whereas patients with only one or two of the “high-risk”
variables had mortality rates of 1.0% and 2.8%, respectively.
DISCUSSION
Although the evidence base supporting CEA as the
gold standard in the treatment of both symptomatic and
asymptomatic carotid stenosis is sound,1-6 CAS has been
proposed as appropriate alternative treatment for carotid
stenosis. A number of randomized controlled trials com-
paring CAS with CEA followed, with variable results, per-
haps reflecting the heterogeneous patient populations stud-
ied.7,8,24-28 The FDA, however, used the findings of these
trials as the basis for its approval of the use of CAS for
treating both symptomatic and asymptomatic patients who
are considered high-risk surgical candidates.
The FDA’s decision was largely based on the SAPPHIRE
trial,7,8 a multicenter, prospective, randomized controlled
trial designed to test the noninferiority of CAS vs CEA in
high-risk surgical patients. A number of methodologic and
statistical problems with the trial have made drawing any
definitive conclusions problematic and controversial.9-12
One such criticism has been the apparently excessive 30-day
stroke/death rate of 5.4% among patients undergoing
CEA, even though 70% of the patients were those with
asymptomatic disease. This rate is much higher than the 3%
rate recommended in the American Heart Association
(AHA) guideline statement for those with asymptomatic
disease.13 The authors of the SAPPHIRE study nonethe-
less concluded that CAS was not inferior to CEA in treating
high-risk patients with carotid artery stenosis.
Two other studies sought to examine outcomes
after CAS in treating the so-called high-risk patients. The
ACCULINK for Revascularization of Carotids in High-
Risk patients (ARCHeR) study defined its high-risk pa-
tients using a combination of physiologic and anatomic
factors.29 It is interesting to note that more than one-third
of the patients in this high-risk group were those with
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risk of embolic stroke from stenting should be quite low
because these lesions are not the typical ulcerated plaques
seen in patients with primary carotid stenosis. Despite this,
the 30-day stroke/death rate was 6.9% for the 581 study
patients. The rate was 11.6% for the symptomatic patients
and 5.4% for the asymptomatic patients, perioperative com-
plication rates again far higher than those recommended by
Table II. Univariate analysis of 30-day stroke in various su
Variable
30-Day str
With variable
“High-Risk” 1.4 (16/1174)
Age 80 y 1.5 (11/737)
Significant cardiac disease
Active CHF 0 (0/53)
Recent MI 1.7 (1/60)
Recent angina 1.9 (2/107)
Severe COPD 1.1 (4/351)
Female gender 2.0 (32/1619)
Height, (inches)a 65.1  4.4 [56-74]
Previous PTCA 2.2 (15/691)
Previous cardiac surgery 1.8 (18/977)
Hypertension 1.7 (57/3380)
CRIc 0.8 (5/600)
Dialysis dependent 2.2 (1/45)
IDDM 2.3 (8/347)
PVD 1.0 (4/394)
CLI 0 (0/42)
Previous neurologic event
Hemiplegia 6.1 (16/263)
CVA with deficit 2.7 (16/595)
CVA without deficit 1.7 (5/302)
TIA 2.0 (23/1127)
Current smoker 1.9 (21/1078)
Dependent functional status 2.4 (6/247)
Previous CEA 0 (0/34)
Intraoperative transfusion 8.6 (3/35)
Total anesthesia time, mina 214.5  188.8 [71-1
CEA, Carotid endarterectomy; CHF, congestive heart failure; CLI, critic
pulmonary disease; IDDM, insulin-dependent diabetes mellitus; MI, myo
vascular disease; TIA, transient ischemic attack.
aFor continuous variables the “With variable” column denotes average valu
among those who did not have postoperative stroke.
bP  .05 indicates significance.
cChronic renal insufficiency defined as serum creatinine 1.5 mg/dL.
Table III. Independent risk factors associated with
30-day stroke and death using logistic regression
Variable OR 95% CI P
Stroke
Intraoperative transfusion 5.95 1.71-20.66 .005
Hemiplegia 5.34 2.96-9.64 .0001
Shorter height 1.09 1.02-1.16 .010
Increased anesthesia time 1.02 1.00-1.03 .008
Death
Critical limb ischemia 12.72 3.49-46.40 .0001
Poor functional status 7.05 2.95-16.82 .0001
CI, Confidence interval; OR, odds ratio.the AHA guidelines.13 Furthermore, the authors used anextremely high 1-year adverse event rate of 14.4% as the
“historical control” for carotid surgery in concluding that
the outcome after CAS was more favorable. This method-
ology is scientifically unsound, however, because many of
the studies used in deriving the “historical control” event
rate were those with combined CEA and coronary artery
bypass grafting surgeries.
Another high-risk CAS registry study is the Boston
Scientific EPI: A Carotid Stenting Trial for High-risk Sur-
gical Patients (BEACH) trial.30 High-risk was again de-
fined using a combination of medical comorbidities and
unfavorable anatomy. Among 480 such high-risk patients,
where 34% were those with restenosis after CEA, combined
30-day stroke/death/MI rate was 5.4%, with only one
patient (0.2%) sustaining an MI. Stroke/death/MI rates
among symptomatic and asymptomatic patients were 7.7%
(0%MI) and 4.7% (0.3% or 1 patient withMI), respectively.
Those withmedical comorbidities had a significantly higher
30-day event rate than those with anatomic high-risk fac-
tors (14.3% vs 5.3%; P  .002), suggesting that patients
with medical comorbidities do not benefit from the sup-
posedly less invasive endovascular treatment. In addition,
ups undergoing carotid endarterectomy
(No) or mean  SD (range)a
Pb valueWithout variable
1.7 (46/2775) .50
1.6 (51/3212) .85
1.6 (62/3896) .99
1.6 (61/3889) .62
1.6 (60/3842) .69
1.6 (58/3598) .65
1.3 (30/2330) .087
66.4  4.1 [48-92] .013
1.4 (47/3258) .16
1.5 (44/2972) .43
0.9 (5/569) .20
1.7 (52/3109) .15
1.6 (61/3904) .51
1.5 (54/3602) .25
1.6 (58/3555) .52
1.6 (62/3907) .99
1.2 (46/3686) .001
1.4 (46/3354) .017
1.6 (57/3647) .81
1.4 (39/2822) .13
1.4 (41/2871) .24
1.5 (56/3702) .26
1.6 (62/3915) .99
1.5 (59/3914) .017
186.9  57.2 [44-1592] .001
b ischemia; CVA, cerebral vascular accident; COPD, chronic obstructive
l infarction; PTCA, percutaneous coronary angioplasty; PVD, peripheral
ng those who had postoperative stroke and the “Without variable” columnbgro
oke, %
558]
al lim
cardia
e amoadvanced age (75 years) was associated with significantly
L.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 2 Kang et al 335worse outcomes. Nonetheless, the authors concluded non-
inferiority of CAS to CEA, again based on a flawed litera-
ture control as in the ARCHeR trial.
Contemporary series of CEAs consistently demonstrate
excellent perioperative outcomes. This was the case in our
study, with 30-day stroke/death rate of 2.2% among 3949
CEAs performed across a spectrum of both academic and
community hospitals. Results are likewise favorable from an
earlier report of the NSQIP database by Stoner et al,14
where the 30-day stroke/death rate was 3.4% among
13622 CEAs performed between 2000 and 2003 (95%
men, 91% VA hospitals). Similar results are reported from a
variety of large population-based studies. After review of
3259 CEAs (42% symptomatic) from the Society for Vas-
cular Surgery carotid vascular registry, Sidawy et al15 re-
ported 30-day stroke/death/MI rate of 3.75% in symp-
tomatic patients and 1.97% in asymptomatic patients.
Timaran et al16 reported in-hospital mortality rate of 0.6%
and stroke rate of 1.1% among 113,000 CEAs (7.6% symp-
tomatic) performed in the United States in 2005 in the
Nationwide Inpatient Sample (NIS) database; whereas,
McPhee et al17 reported an in-hospital mortality rate of
Table IV. Univariate analysis of 30-day mortality in vario
Variable
30-Day mort
With variable
“High-risk” 1.3 (15/1174)
Age 80 y 0.9 (7/737)
Significant cardiac disease
Active CHF 7.5 (4/53)
Recent MI 5.0 (3/60)
Recent angina 0.9 (1/107)
Severe COPD 1.4 (5/351)
Female gender 0.8 (13/1619)
Height, (inches)a 64.9  4.5 [56-72]
Previous PTCA 0.9 (6/691)
Previous cardiac surgery 0.5 (5/977)
Hypertension 0.7 (24/3380)
CRIc 1.5 (9/600)
Dialysis dependent 4.4 (2/45)
IDDM 1.4 (5/347)
PVD 1.5 (6/394)
CLI 7.1 (3/42)
Previous neurologic event
Hemiplegia 2.7 (7/263)
CVA with deficit 1.7 (10/595)
CVA without deficit 0.7 (2/302)
TIA 0.3 (3/1127)
Current smoker 0.8 (9/1078)
Dependent functional status 3.6 (9/247)
Previous CEA 2.9 (1/34)
Intraoperative transfusion 2.9 (1/35)
Total anesthesia time, mina 211.1  71.6 [100-3
CEA, Carotid endarterectomy; CHF, congestive heart failure; CLI, critic
pulmonary disease; IDDM, insulin-dependent diabetes mellitus; MI, myo
vascular disease; TIA, transient ischemic attack.
aFor continuous variables “With variable” column denotes average value am
those who did not have postoperative stroke.
bP  .05 indicates significance.
cChronic renal insufficiency (CRI) defined as serum creatinine 1.5 mg/d0.9% and a stroke rate of 0.4% among 245,000 CEAs (8%symptomatic) performed in 2003 and 2004 (NIS data-
base).17
We previously published a series of 2236 isolated CEAs
(36% symptomatic) performed between 1989 and 1999
with a 30-day stroke/death rate of 1.4%.30 Furthermore, a
36% reduction in perioperative morbidity/mortality oc-
curred in the last 5 years of the study compared with the
previous 5 years (7.5% vs 4.8%; P  .006). Other studies
have also demonstrated improving outcomes after CEA.
Matsen et al18 reported an in-hospital stroke/death rate of
1.3% among nearly 24,000 CEAs (15.2% symptomatic)
performed in Maryland between 1994 and 2003 and ob-
served improvement in stroke rate during the study period
of 2.12% in 1994, 1.47% in 1995, and 0.29% to 0.65% from
1996 to 2003. Similarly, Sheikh et al19 reported decreasing
30-day mortality after CEA among Medicare beneficiaries
from 1991 to 2000: 1.95% in 1991, 1.44% in 1995, and
0.89% in 2000 (P  .001). Finally, Kragsterman et al20
reviewed CEA outcomes on all asymptomatic patients un-
dergoing CEA in Sweden between 1994 and 2003 and
reported that the stroke/death rate of 2.1% in asymptom-
atic patients during the entire period improved to 0.9%
bgroups undergoing carotid endarterectomy
% (No.) or mean  SD (range)a
Pb valueWithout variable
0.4 (11/2775) .002
0.6 (19/3212) .28
0.6 (22/3896) .001
0.6 (23/3889) .007
0.7 (25/3842) .51
0.6 (21/3598) .06
0.6 (13/2330) .35
66.4  4.1 [48-82] .07
0.6 (20/3258) .045
0.7 (21/2972) .51
0.4 (2/569) .33
0.5 (16/3108) .007
0.6 (24/3904) .035
0.6 (21/3602) .059
0.6 (20/3555) .025
0.6 (23/3907) .002
0.5 (19/3686) .001
0.5 (16/3354) .001
0.7 (24/3647) .99
0.8 (23/2822) .08
0.6 (17/2871) .40
0.5 (17/3702) .001
0.6 (25/3915) .20
0.6 (25/3914) .21
187.2  61.4 [44-1592] .048
b ischemia; CVA, cerebral vascular accident; COPD, chronic obstructive
l infarction; PTCA, percutaneous coronary angioplasty; PVD, peripheral
hose who had postoperative stroke and “Without variable” column amongus su
ality,
76]
al lim
cardia
ong tfrom 1999 to 2003 (P  .026).
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sults are achieved in contemporary practice across a broad
spectrum of surgical practices, not just in tertiary care
centers.
A number of recent studies also document favorable
results even among the so-called high-risk patients. In our
study, 30-day stroke/death rate among “high-risk” pa-
tients was 2.5% compared with 2.0% in the non-“high-risk”
group (P  .371). Similarly, Flanigan et al31 compared
results of 207 SAPPHIRE-eligible high-risk vs 235 normal-
risk patients (39% symptomatic) and saw no difference in
30-day outcomes. In a retrospective review of 776 CEAs
performed at the Mayo Clinic between 1998 and 2002
(27% symptomatic; 42% SAPPHIRE-eligible), Mozes
et al32 reported no significant difference in perioperative
stroke/death rates between the high- and low-risk patients
(2.5% vs 1.1%). Boules et al33 defined high-risk using
similar criteria consisting of medical or anatomic factors, or
both.33 After reviewing 499 CEAs from 1996 to 2001
(39% symptomatic; 17% high-risk), the authors found no
difference in 30-day poor outcome (stroke/TIA/death)
between high- and low-risk patients (4.8% vs 4.1%; P 
.77). Others also reported no significant difference in peri-
operative outcomes when high-risk was defined as North
American Symptomatic Carotid Endarterectomy Trial
(NASCET)/Asymptomatic Carotid Atherosclerosis Study
(ACAS) ineligible or ARCHeR eligible.34,35
Advanced age is often included in high-risk criteria.
However, a review of contemporary results for CEAs per-
formed among 2564 octogenarians revealed a 30-day
stroke/death rate of 3.5%.36 This was recapitulated in our
study, where the 30-day stroke/death rate among patients
aged80 years was 2.3% compared with 2.1% among those
aged 80 years (P  .749). In contrast, evidence suggests
that the risk among octogenarians after CAS is much
higher. The Carotid Revascularization Endarterectomy vs
Stenting Trial (CREST) is an ongoing, multicenter, ran-
domized controlled trial comparing CAS vs CEA. In their
lead-in phase report, Hobson et al28 examined outcomes
after 749 CAS procedures (31% symptomatic) and reported
that the 30-day stroke/death rate was significantly higher
among octogenarians (12.1% vs 3.2%; P  .0001), mainly
secondary to a significantly higher 30-day stroke rate
(12.1% vs 2.8%; P  .0001).28 Others have also reported
increased adverse periprocedural outcomes among older
patients undergoing CAS and suggested that increasing age
may be a surrogate for unfavorable anatomy.37-39 The bulk
of evidence establishes CEA as the safer carotid interven-
tion in octogenarians.
In our study, independent risk factors associated with
stroke were the need for intraoperative transfusion, prior
major stroke, shorter height, and increased anesthesia time.
Need for intraoperative transfusion and increased anesthe-
sia time indicate technical difficulties during the procedure.
To assess whether increased anesthesia time was due to
patient comorbidities, analysis was performed after adjust-
ing for American Society of Anesthesiologists (ASA) class;
longer anesthesia time was still associated with increasedrisk for stroke. Shorter height, a surrogate for smaller artery
size, also increased the risk of stroke. Previous studies have
shown that height affects carotid artery size, and that
shorter height is associated with increased risk after
CEA.40,41 The perioperative risk after CEA has been re-
ported to be higher in women than in men, and the benefit
of CEA for women has been questioned.42-44 This differ-
ence in perioperative risk may have been at least partly
secondary to the difference in body size between men and
women, where both the artery diameter and surgical expo-
sure can be related to the patient’s height. In our study,
men were significantly taller than women and there was a
trend toward increased risk for stroke in women (P .087).
After adjusting for height, this trend was no longer ob-
served.
Risk factors associated with perioperative mortality
were poor functional status and CLI, a surrogate for diffuse
advanced atherosclerotic disease. Functional status is a
unique variable available in the NSQIP database, where a
patient’s preoperative functional status is clearly defined
and categorized (Appendix). These two variables point to a
patient population with advanced systemic illness that is at
increased risk of death after CEA; a logical conclusion
would be that carotid intervention for asymptomatic dis-
ease is inappropriate in such patients. This is supported by
the significant linear relationship between the number of
high-risk variables and perioperative death, such that
among patients with all three high-risk systemic variables,
30-day mortality was 14.3%, although only seven patients
met these criteria of having all three variables. This relation-
ship was not present for stroke.
Only three patients had a fatal stroke after CEA, sug-
gesting that the patient groups at risk of stroke vs death
after CEA were quite different. Although lacking definitive
anatomic data such as history of previous neck irradiation or
radical neck dissection, our data suggest that variables
associated with increased risk of stroke may be related to
anatomic and technical features, whereas variables associ-
ated with increased risk of death are related to serious
systemic comorbidities.
Systemic comorbidities did not increase risk of stroke
after CEA. Previous studies examining outcomes after
CAS among the so-called high-risk surgical patients
(SAPPHIRE, ARCHeR, and BEACH trials), defined
such patients using both anatomic and physiologic crite-
ria. Although there may be technical advantages of CAS
over CEA among patients with “anatomic” risk factors, it is
unknown if CAS will result in better or even equal out-
comes for those with advanced systemic illness. Such pa-
tients, if asymptomatic, are likely better served by conser-
vative medical management rather than undergoing any
intervention at all; thus far, no study has adequately ad-
dressed this issue. Because much of the literature on CAS
defines high-risk patients using both anatomic and systemic
criteria, it is unclear if the noninferiority of CAS to CEAwas
secondary to anatomic risk factors alone.7,8,29,30 It will be
important to distinguish between the two groups and assess
outcomes separately in future studies.
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include inherent problems of analysis using a large data-
base, such as imprecise coding. Information on the degree
of carotid artery stenosis, timing, and laterality of previous
neurologic event, and various other anatomic information
including history of previous neck irradiation and contralat-
eral carotid occlusion are not available and thus limit the
interpretation of the study findings.
Although 30% of the patients in the study met the
criteria for “high-risk,” only a small proportion of patients
met the criteria for active cardiac disease, which may repre-
sent surgical selection bias. However, it is also important to
note that the inclusion criteria for the SAPPHIRE trial was
not a rigorous one in that patients only needed to have one
of the “high-risk” variables to be considered eligible for the
trial.
One of themain advantages of theNSQIPdatabase is that
it offers independent adjudication of 30-day outcomes by a
nonpartial party, namely by a trained clinical nurse–reviewer.
This methodology has been previously validated.22,23 We
acknowledge that this is different from examination by an
independent neurologist, but neurologic outcomes affect-
ing activities of daily living will not be missed. In addition,
our study reports true 30-day outcomes compared with
studies based on state and nation-wide registries that rely
on discharge data and may therefore underestimate true
perioperative complication rates after CEA. In fact, in our
study only 39 of 62 strokes (62.9%) and 12 of 26 deaths
(46.2%) were observed before discharge from the initial
hospitalization, indicating the valid capture of postdis-
charge events.
CONCLUSIONS
CEA is associated with favorable 30-day outcomes
across a spectrum of patient comorbidity features, includ-
ing octogenarian status. These data indicate that anatomic
and intraoperative technical features are important predic-
tors of perioperative stroke. Advanced systemic illness, in
the form of CLI and poor functional status, is an important
predictor of death for patients undergoing CEA, represent-
ing circumstances wherein a noninterventional posture
should be undertaken for those with asymptomatic disease.
While CAS may have a potential role in treating patients
with certain anatomic features, our data refute the concept
that CAS is preferred for patients deemed high-risk by
virtue of systemic comorbidities.
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Dr Amy Reed (Cincinnati, OH). Were you able to look at the
asymptomatic vs symptomatic indication for carotid endarterec-
tomy and particularly look at how those high-risk patients did?
There have been studies that have shown that that is a particular
area where patients don’t do well and whether or not best medical
management might be better.
Dr Jeanwan Kang. The information that is available in the
NSQIP database is a history of previous neurologic event. What we
don’t know is the laterality or the timing of that event, so we are
not able to determine who underwent the surgery for symptomatic
vs asymptomatic disease.
What we are able to determine from the database is a group of
patient population who, for sure, is asymptomatic, mainly those
with absolutely no previous neurologic event, and in those patients
there was a slightly lower rate of stroke death rate, however it was
not statistically significant.
Dr Hasan Dosluoglu (Buffalo, NY). I enjoyed the talk and a
wealth of information from the private NSQIP data is going to
start coming out. I am surprised that 80% of the patients hadprocedure, I am surprised at that. Did the high-risk patients have
different outcomes in those who had a general anesthesia vs local
anesthesia? And second, maybe the high-risk patients were not too
high risk, because they could undergo general anesthesia in those
who had general anesthesia.
Dr Kang. To answer your first question, because the percent-
age of patients undergoing local anesthesia was less than 20%, that
came out to about a little over 600 patients undergoing carotid
endarterectomy under local anesthesia, so any sort of subanalysis
became meaningless because the numbers were so low.
The criteria for high risk were the same as that defined by the
SAPPHIRE study and there were about 30% of patients who met
these criteria. In addition, ASA [American Society of Anesthesiol-
ogists] class for each patient is available in the NSQIP database. I
have not shown these data here, but patients who were ASA class 3
or 4 made up majority of the patient population.
Dr Anton Sidawy (Washington, DC). We analyzed the VA
NSQIP data. There were over 20,000 carotid endarterectomies.
Although there was no significant difference in neurologic out-
comes based on different levels of renal insufficiency, 30-day
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were significantly increased. Have you adjusted your data for renal
failure?
DrKang. It certainly was. For stroke, renal failure was not one
of the variables that came out to be significant on univariate
analysis. And we looked at renal failure in many different ways. We
looked at it as a categorical variable as well as continuous variable.
We also calculated GFR and none of that made a difference interms of univariate analysis for stroke.It was, however, one of the
variables that came out to be significant for death. However, on
multivariate analysis, it was not one of the independent predictors
of death.
Having said that, the number of deaths that were studied in
our study were only 26; and so therefore, we could only say that
two of the highest, most significant variables on this multivariate
analysis were significant predictors of death.
ion; PTCA, percutaneous coronary angioplasty; PVD, peripheral vascular disease;
nt ischemic attack; VSD, ventricular septal defect.
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Variable
CHF Newly diagnosed CHF with
or symptoms in the 30 da
MI History of a non-Q wave or
Angina History of angina 30 days
COPD COPD resulting in any one
● Functional disability fr
● Hospitalization in the
● Requires chronic bronc
● An FEV1 of 75% of p
Previous PTCA Previous coronary intervent
dilatation or stent placem
Previous cardiac surgery Any major cardiac surgical p
Includes CABG, valve rep
vessel repair, cardiac trans
not include pacemaker in
Hypertension Persistent elevation of SBP
antihypertensive treatmen
(which should be 30 da
CRI Serum creatinine 1.5 mg/
Dialysis dependent Acute or chronic renal failu
hemofiltration, hemodiafi
IDDM Diabetes requiring daily ins
PVD Any type of angioplasty or r
disease or a patient who h
disease.
CLI Rest pain or gangrene at th
Previous neurologic event
Hemiplegia Total or partial paralysis or
CVA with deficit Embolic, thrombotic, or he
dysfunction (eg, hemiple
CVA without deficit Embolic, thrombotic, or he
no current residual neuro
TIA Focal neurologic deficits of
Dependent functional status Requires some or total assis
considered for surgery (n
who is able to function in
bathing, feeding, dressing
ADL, Activities of daily living; ASD, atrial septal defect; CABG, coronary a
COPD, chronic obstructive pulmonary disease;CPB, cardiopulmonary bypas
vascular accident; CVA, cerebrovascular accident; DBP, diastolic blood pr
diabetes mellitus; LVAD, left ventricular assist device;MI,myocardial infarct
PVD, peripheral vascular disease; SBP, systolic blood pressure; TIA, transieDefinition
in the previous 30 days or a diagnosis of chronic CHF with new signs
ys before surgery.
a Q wave infarct 6 months before surgery.
before surgery.
or more of the following:
om COPD (eg dyspnea, inability to perform ADLs)
past for treatment of COPD
hodilator therapy with oral or inhaled agents
redicted on pulmonary function testing
ion, including any attempted interventions. Includes balloon
ent, but not valvuloplasties.
rocedure performed either as an “off-pump” repair or using CPB.
lacement or repair, repair of ASD or VSD defects, great thoracic
plant, left ventricular aneurysmectomy, insertion of LVAD, etc. Does
sertions or automatic implantable cardioverter defibrillator insertions.
140 mm Hg or a DBP 90 mm Hg, or requires an
t at the time the patient is being considered as a candidate for surgery
ys before surgery).
dL.
re requiring treatment with peritoneal dialysis, hemodialysis,
ltration, or ultrafiltration 2 weeks before surgery.
ulin therapy.
evascularization procedure for atherosclerotic peripheral vascular
as had any type of amputation procedure for peripheral vascular
e time of surgery.
paresis of one side of the body (not a single limb).
morrhagic CVA with persistent residual motor, sensory, or cognitive
gia, hemiparesis, aphasia, sensory deficit, impaired memory).
morrhagic CVA with neurologic deficit(s) lasting at 30 minutes, but
logic dysfunction or deficit.
sudden onset and brief duration. These attacks may be recurrent.
tance from another person for ADLs at the time the patient is being
o longer than 30 days before surgery). This does not include a person
dependently with prosthetics, equipment, or devices. ADLs include:
, toileting, and mobility.
rtery bypass grafting; CHF, congestive heart failure; CLI, critical limb ischemia;
s;CRI, chronic renal insufficiency;CRI, chronic renal insufficiency;CVA, cerebral
essure; FEV1, forced expiratory volume in 1 second; IDDM, insulin-dependent
